Skip to content
Menu

Oppenheimer Maintains Outperform on Tvardi Therapeutics, Lowers Price Target to $9

Benzinga Newsdesk 21 hours ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Oppenheimer analyst Jay Olson maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Outperform and lowers the price target from $10 to $9.

Oppenheimer analyst Jay Olson maintains Tvardi Therapeutics (NASDAQ:TVRD) with a Outperform and lowers the price target from $10 to $9.

Read at benzinga.com